Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Work In Process (2016 - 2026)

Heron Therapeutics filings provide 11 years of Work In Process readings, the most recent being $21.6 million for Q1 2026.

  • On a quarterly basis, Work In Process fell 25.32% to $21.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.6 million, a 25.32% decrease, with the full-year FY2025 number at $26.6 million, down 2.12% from a year prior.
  • Work In Process hit $21.6 million in Q1 2026 for Heron Therapeutics, down from $26.6 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $29.0 million in Q1 2025 to a low of $9.0 million in Q2 2023.
  • Median Work In Process over the past 5 years was $18.4 million (2024), compared with a mean of $19.5 million.
  • Biggest five-year swings in Work In Process: plummeted 55.18% in 2023 and later surged 86.87% in 2024.
  • Heron Therapeutics' Work In Process stood at $20.7 million in 2022, then dropped by 29.79% to $14.6 million in 2023, then surged by 86.87% to $27.2 million in 2024, then decreased by 2.12% to $26.6 million in 2025, then dropped by 18.75% to $21.6 million in 2026.
  • The last three reported values for Work In Process were $21.6 million (Q1 2026), $26.6 million (Q4 2025), and $26.3 million (Q3 2025) per Business Quant data.